Developer docs
API playgroundTry for free, no card

Search company profiles

Lifecore Biomedical

Full company profile

uuid0000a51

Namestring
Lifecore Biomedical
Legal namestring
Lifecore Biomedical LLC
Websiteurl
lifecore.com
Company typeenum
Public
Founded yearint
1965
Descriptiontext

Lifecore Biomedical (NASDAQ: LFCR) is a contract development and manufacturing organization (CDMO) headquartered in Chaska, Minnesota, specializing in sterile injectable pharmaceutical manufacturing. Founded in 1965 and spun off from Landec Corporation in November 2022, the company operates across a 248,000 sq ft campus comprising headquarters, manufacturing, and warehouse facilities. With a 40+ year global regulatory track record, multi-compendial quality management system, and products that have impacted more than 150 million patients worldwide, Lifecore serves pharmaceutical, biotechnology, and medical device customers requiring aseptic fill-finish, process development, analytical testing, and stability services for sterile injectables.

The company's technology platform centers on proprietary High-Pressure Sterile Filtration (HPSF) operating up to 900 psi, enabling processing of high-viscosity formulations exceeding 100,000 cP that standard CDMO equipment cannot handle. It operates ISO 5 Grade A aseptic filling lines for vials (2R-100R), syringes (0.5mL-10mL), and cartridges under Annex 1 conditions, with phase-appropriate compliance for pre-clinical through commercial programs. Lifecore also produces sodium hyaluronate (NaHy) through bacterial fermentation, making it the only CDMO that vertically integrates its own NaHy raw material supply with sterile fill-finish services. Other differentiated offerings include Corgel BioHydrogel (licensed from Cleveland Clinic) and methacrylated sodium hyaluronate for 3D bioprinting and biological scaffolding.

Lifecore generates revenue through two primary streams: project-based CDMO manufacturing contracts (clinical and commercial) and unit-priced sodium hyaluronate product sales (research-grade powder at $150-790 per bottle, Corgel BioHydrogel kits, methacrylated NaHy, and GMP custom modifications). The go-to-market approach combines enterprise field sales for CDMO contracts with e-commerce ordering for smaller research customers and an active presence at industry conferences (DCAT Week, BIO International, CPhI, CDMO Live). Management has set 2029 targets of $212-225M in revenue and 25%+ Adjusted EBITDA margins, contingent on lifting capacity utilization from current levels toward 60%, supported by recent additions of seven late-stage program agreements in seven months.

Short descriptiontext

Lifecore Biomedical is a publicly-traded CDMO specializing in sterile injectable pharmaceutical manufacturing and sodium hyaluronate production for pharmaceutical, biotech, and medical device companies, leveraging proprietary high-viscosity filtration technology across its 248,000 sq ft Minnesota campus.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersChaska, United States
HQ citystring
Chaska
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, contract development manufacturing, sodium hyaluronate production, aseptic fill-finish services, pharmaceutical CDMO services
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Sterile Injectable CDMO
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Manufacturing Services
TypeProfessional Services
Description

Contract development and manufacturing services for sterile injectable pharmaceutical products including formulation, fill-finish, analytical testing, and packaging. Revenue is generated through project-based contracts with pharmaceutical and biotech companies for clinical and commercial manufacturing.

lifecore.com
2Sodium Hyaluronate Products
TypeOne Time License
Description

Sale of sodium hyaluronate (NaHy) in various grades including research-use, GMP injectable-grade, hydrogels (Corgel BioHydrogel), and methacrylated NaHy. Products sold in standardized molecular weight ranges with pricing based on quantity and specifications.

lifecore.com
3Development Services
TypeProfessional Services
Description

Technical transfer and process development services for customers, including formulation optimization, tech transfer, and clinical batch manufacturing for early-stage programs.

in.investing.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details5 tiers
1Research-Use Sodium Hyaluronate 1g bottles
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices range from $150-$210 per bottle depending on molecular weight. Lower molecular weights (<500K) are $210; higher weights (500K-1.8M) are $150 per bottle.

lifecore.com
2Research-Use Sodium Hyaluronate 5g bottles
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices range from $475-$790 per bottle. Lower molecular weights are $790; higher weights (500K+) are $475 per bottle.

lifecore.com
3Corgel BioHydrogel Kits
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$185 per kit (1%, 3%, or 5% Gel Kit). Sample Gel Pack (one of each) is $525. Powder only options at $160.

lifecore.com
4Methacrylated Sodium Hyaluronate (MeHa)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

0.5g bottles: $255 (any DOS). 1g bottles: $455 (any DOS). 5g bottles: $2,045 (any DOS). DOS = Degree of Substitution (20%, 40%, or 60%).

lifecore.com
5CDMO Services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for contract manufacturing services. Custom quotes available through online inquiry form.

lifecore.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Corgel® BioHydrogel
Description

Biocompatible hyaluronan hydrogel technology licensed from Cleveland Clinic, used for research purposes in drug delivery applications. Meets ISO 10993 safety and toxicity standards.

lifecore.com
+1 more record
Core offering1 text field

Lifecore Biomedical operates as a contract development and manufacturing organization (CDMO) providing end-to-end sterile injectable pharmaceutical services, including process development, aseptic formulation, fill-finish manufacturing (vials, syringes, cartridges), analytical testing, stability studies, and regulatory-compliant packaging. The company also produces premium sodium hyaluronate (NaHy) via microbial fermentation, sold as research-grade powder, hydrogels, methacrylated variants, and custom GMP-modified products for use as API, excipient, or research material.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • No batch rejected in 1.5 years of operations with 11.5 million vials manufactured and released
+3 more records
Product overview1 text field

Lifecore Biomedical operates as a dual-business contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals and sodium hyaluronate (NaHy) products. The company offers CDMO Services as its primary platform, encompassing Process Development, Aseptic Manufacturing (fill-finish for vials, syringes, and cartridges), Analytical & Stability Testing, and Quality & Compliance support. Alongside the CDMO platform, Lifecore manufactures a portfolio of Sodium Hyaluronate Products including Research-Use Powder, Corgel BioHydrogel, Methacrylated Sodium Hyaluronate (MeHa), and GMP/Custom Modifications. The CDMO services leverage NaHy manufacturing expertise to support complex injectable formulations, while the NaHy product line serves as both a standalone offering and demonstrates manufacturing capabilities to prospective CDMO customers.

Product and service1 record
1CDMO Services
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierGrowthTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Manufacturing agreement for injectable suspension product for neurological disorders. Lifecore handling technical transfer and commercial production at U.S. operations. Seventh late-stage program addition in seven months.

Strategic tierGrowthTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Development services agreement for DT-001 drug candidate (corticosteroid for inflammatory acne lesions) with Indomo's ClearPen self-injection device. Lifecore producing engineering and clinical batches for Phase 2 trials.

3Large Global Pharmaceutical Customer (unnamed)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

CDMO master services agreement for development services and technology transfer of injectable pharmaceutical product. Expected to become one of Lifecore's top five commercial customers. Second multinational agreement in three months.

finance.yahoo.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Selected as new commercial manufacturing partner to transfer manufacturing of a leading injectable pharmaceutical product. Represents company's second agreement with the same multinational organization, emphasizing growing reputation.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Collaboration agreement providing integrated, end-to-end solution for peptide-based pharmaceutical customers. Combines PolyPeptide's peptide manufacturing with Lifecore's fill-finish capabilities.

Strategic tierKeyTypeGTM or Marketing PartnerAnnounced on2024-03-01
Description

Co-marketing partnership agreement to enable both companies to provide unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Small-cap public CDMO focused on sterile injectable manufacturing for commercial and clinical-stage products. Highly comparable size, business model, and customer base to Lifecore.

TypeDirect peer
Description

Large-scale CDMO with broad sterile injectable fill-finish capabilities and a global manufacturing footprint. Catalent competes with Lifecore for pharmaceutical and biotech customers needing aseptic manufacturing, though its portfolio is far broader.

TypeBroad incumbent
Description

Global CDMO incumbent with sterile injectable, biologic, and API manufacturing services. Comparable to Lifecore in serving pharma and biotech customers seeking complex injectable manufacturing, but at substantially larger scale.

TypeDirect peer
Description

Specialist CDMO focused on aseptic fill-finish of sterile injectables including prefilled syringes, cartridges, and vials. Highly comparable to Lifecore's core CDMO service offering and target customer base.

5Recipharm
TypeDirect peer
Description

European-headquartered CDMO providing sterile fill-finish and injectable manufacturing services to pharma and biotech customers. Direct competitor for sterile injectable contract manufacturing contracts.

TypeBroad incumbent
Description

Large Asian CDMO offering sterile injectable and biologic fill-finish services globally. Competes with Lifecore for pharma outsourcing customers, particularly in technical transfer and commercial manufacturing.

TypeBroad incumbent
Description

Operates one of the largest pharma services networks through Patheon, providing sterile injectable and aseptic fill-finish capabilities. Competes broadly with Lifecore for pharmaceutical CDMO customers.

TypeDirect peer
Description

CDMO offering sterile injectable development and manufacturing services to pharma and biotech customers. Comparable service mix in fill-finish and analytical testing for injectable products.

TypeEmerging player
Description

US-based emerging CDMO specializing in aseptic fill-finish of injectable products. Comparable in scale and capability profile to Lifecore, serving similar small-to-mid pharma and biotech customers.

10Bloomage Biotech
TypeDirect peer
Description

Global leader in hyaluronic acid/sodium hyaluronate fermentation and supply for medical, aesthetic, and pharmaceutical applications. Comparable to Lifecore's NaHy product line and competes for OEM pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lifecore Biomedical

Sterile Injectable CDMOlifecore.com

Lifecore Biomedical is a publicly-traded CDMO specializing in sterile injectable pharmaceutical manufacturing and sodium hyaluronate production for pharmaceutical, biotech, and medical device companies, leveraging proprietary high-viscosity filtration technology across its 248,000 sq ft Minnesota campus.

What Lifecore Biomedical does

Lifecore Biomedical (NASDAQ: LFCR) is a contract development and manufacturing organization (CDMO) headquartered in Chaska, Minnesota, specializing in sterile injectable pharmaceutical manufacturing. Founded in 1965 and spun off from Landec Corporation in November 2022, the company operates across a 248,000 sq ft campus comprising headquarters, manufacturing, and warehouse facilities. With a 40+ year global regulatory track record, multi-compendial quality management system, and products that have impacted more than 150 million patients worldwide, Lifecore serves pharmaceutical, biotechnology, and medical device customers requiring aseptic fill-finish, process development, analytical testing, and stability services for sterile injectables.

The company's technology platform centers on proprietary High-Pressure Sterile Filtration (HPSF) operating up to 900 psi, enabling processing of high-viscosity formulations exceeding 100,000 cP that standard CDMO equipment cannot handle. It operates ISO 5 Grade A aseptic filling lines for vials (2R-100R), syringes (0.5mL-10mL), and cartridges under Annex 1 conditions, with phase-appropriate compliance for pre-clinical through commercial programs. Lifecore also produces sodium hyaluronate (NaHy) through bacterial fermentation, making it the only CDMO that vertically integrates its own NaHy raw material supply with sterile fill-finish services. Other differentiated offerings include Corgel BioHydrogel (licensed from Cleveland Clinic) and methacrylated sodium hyaluronate for 3D bioprinting and biological scaffolding.

Lifecore generates revenue through two primary streams: project-based CDMO manufacturing contracts (clinical and commercial) and unit-priced sodium hyaluronate product sales (research-grade powder at $150-790 per bottle, Corgel BioHydrogel kits, methacrylated NaHy, and GMP custom modifications). The go-to-market approach combines enterprise field sales for CDMO contracts with e-commerce ordering for smaller research customers and an active presence at industry conferences (DCAT Week, BIO International, CPhI, CDMO Live). Management has set 2029 targets of $212-225M in revenue and 25%+ Adjusted EBITDA margins, contingent on lifting capacity utilization from current levels toward 60%, supported by recent additions of seven late-stage program agreements in seven months.

Lifecore Biomedical firmographics

Firmographics
Name
Lifecore Biomedical
Legal name
Lifecore Biomedical LLC
Website
https://lifecore.com
Company type
Public
Founded year
1965
Operating status
Operating
Headcount range
251–500 employees
Short description
Lifecore Biomedical is a publicly-traded CDMO specializing in sterile injectable pharmaceutical manufacturing and sodium hyaluronate production for pharmaceutical, biotech, and medical device companies, leveraging proprietary high-viscosity filtration technology across its 248,000 sq ft Minnesota campus.
Ownership category
akta.pro rank

Lifecore Biomedical industry classification

Industry
Product category
Sterile Injectable CDMO
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Contract development manufacturing
  • Sodium hyaluronate production
  • Aseptic fill-finish services
  • Pharmaceutical CDMO services

Where Lifecore Biomedical is headquartered

Location

Headquarters

HQ city
Chaska
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Lifecore Biomedical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Contract development and manufacturing services for sterile injectable pharmaceutical products including formulation, fill-finish, analytical testing, and packaging. Revenue is generated through project-based contracts with pharmaceutical and biotech companies for clinical and commercial manufacturing.
  2. Sodium Hyaluronate Products: Sale of sodium hyaluronate (NaHy) in various grades including research-use, GMP injectable-grade, hydrogels (Corgel BioHydrogel), and methacrylated NaHy. Products sold in standardized molecular weight ranges with pricing based on quantity and specifications.
  3. Development Services: Technical transfer and process development services for customers, including formulation optimization, tech transfer, and clinical batch manufacturing for early-stage programs.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goResearch-Use Sodium Hyaluronate 1g bottles
Unit PricingPay-as-you-goResearch-Use Sodium Hyaluronate 5g bottles
Unit PricingPay-as-you-goCorgel BioHydrogel Kits
Unit PricingPay-as-you-goMethacrylated Sodium Hyaluronate (MeHa)
OtherMulti-year contractCDMO Services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Lifecore Biomedical product offering

Product offering

Core offering

Lifecore Biomedical operates as a contract development and manufacturing organization (CDMO) providing end-to-end sterile injectable pharmaceutical services, including process development, aseptic formulation, fill-finish manufacturing (vials, syringes, cartridges), analytical testing, stability studies, and regulatory-compliant packaging. The company also produces premium sodium hyaluronate (NaHy) via microbial fermentation, sold as research-grade powder, hydrogels, methacrylated variants, and custom GMP-modified products for use as API, excipient, or research material.

Product overview

Lifecore Biomedical operates as a dual-business contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals and sodium hyaluronate (NaHy) products. The company offers CDMO Services as its primary platform, encompassing Process Development, Aseptic Manufacturing (fill-finish for vials, syringes, and cartridges), Analytical & Stability Testing, and Quality & Compliance support. Alongside the CDMO platform, Lifecore manufactures a portfolio of Sodium Hyaluronate Products including Research-Use Powder, Corgel BioHydrogel, Methacrylated Sodium Hyaluronate (MeHa), and GMP/Custom Modifications. The CDMO services leverage NaHy manufacturing expertise to support complex injectable formulations, while the NaHy product line serves as both a standalone offering and demonstrates manufacturing capabilities to prospective CDMO customers.

Differentiator

Problem solved

Functional benefit

Brands

  • Corgel® BioHydrogel: Biocompatible hyaluronan hydrogel technology licensed from Cleveland Clinic, used for research purposes in drug delivery applications. Meets ISO 10993 safety and toxicity standards.
  • Methacrylated Sodium Hyaluronate (MeHa)

Products and services

  • CDMO Services

Quantifiable outcome

  • No batch rejected in 1.5 years of operations with 11.5 million vials manufactured and released
  • +3 more outcomes

Companies that use Lifecore Biomedical

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Lifecore Biomedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Lifecore Biomedical partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered growth, flagship and key.

  • Global Pharmaceutical Company (unnamed)growthStrategic or Co-development Partner · 15 June 2026Manufacturing agreement for injectable suspension product for neurological disorders. Lifecore handling technical transfer and commercial production at U.S. operations. Seventh late-stage program addition in seven months.
  • IndomogrowthStrategic or Co-development Partner · 4 March 2026Development services agreement for DT-001 drug candidate (corticosteroid for inflammatory acne lesions) with Indomo's ClearPen self-injection device. Lifecore producing engineering and clinical batches for Phase 2 trials.
  • Large Global Pharmaceutical Customer (unnamed)flagshipStrategic or Co-development Partner · 17 December 2025CDMO master services agreement for development services and technology transfer of injectable pharmaceutical product. Expected to become one of Lifecore's top five commercial customers. Second multinational agreement in three months.
  • Global Pharmaceutical Company (unnamed)flagshipStrategic or Co-development Partner · 29 October 2025Selected as new commercial manufacturing partner to transfer manufacturing of a leading injectable pharmaceutical product. Represents company's second agreement with the same multinational organization, emphasizing growing reputation.
  • PolyPeptidekeyStrategic or Co-development Partner · 1 March 2024Collaboration agreement providing integrated, end-to-end solution for peptide-based pharmaceutical customers. Combines PolyPeptide's peptide manufacturing with Lifecore's fill-finish capabilities.
  • SHL MedicalkeyGTM or Marketing Partner · 1 March 2024Co-marketing partnership agreement to enable both companies to provide unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Lifecore Biomedical competitors and assessment

Company assessment

Direct peers

  • Societal CDMO: Small-cap public CDMO focused on sterile injectable manufacturing for commercial and clinical-stage products. Highly comparable size, business model, and customer base to Lifecore.
  • Catalent: Large-scale CDMO with broad sterile injectable fill-finish capabilities and a global manufacturing footprint. Catalent competes with Lifecore for pharmaceutical and biotech customers needing aseptic manufacturing, though its portfolio is far broader.
  • Vetter Pharma: Specialist CDMO focused on aseptic fill-finish of sterile injectables including prefilled syringes, cartridges, and vials. Highly comparable to Lifecore's core CDMO service offering and target customer base.
  • Recipharm: European-headquartered CDMO providing sterile fill-finish and injectable manufacturing services to pharma and biotech customers. Direct competitor for sterile injectable contract manufacturing contracts.
  • Alcami Corporation: CDMO offering sterile injectable development and manufacturing services to pharma and biotech customers. Comparable service mix in fill-finish and analytical testing for injectable products.
  • Bloomage Biotech: Global leader in hyaluronic acid/sodium hyaluronate fermentation and supply for medical, aesthetic, and pharmaceutical applications. Comparable to Lifecore's NaHy product line and competes for OEM pharma customers.

Broad incumbents

  • Lonza Group: Global CDMO incumbent with sterile injectable, biologic, and API manufacturing services. Comparable to Lifecore in serving pharma and biotech customers seeking complex injectable manufacturing, but at substantially larger scale.
  • WuXi AppTec / WuXi Biologics: Large Asian CDMO offering sterile injectable and biologic fill-finish services globally. Competes with Lifecore for pharma outsourcing customers, particularly in technical transfer and commercial manufacturing.
  • Thermo Fisher Scientific (Patheon): Operates one of the largest pharma services networks through Patheon, providing sterile injectable and aseptic fill-finish capabilities. Competes broadly with Lifecore for pharmaceutical CDMO customers.

Emerging players

  • Grand River Aseptic Manufacturing: US-based emerging CDMO specializing in aseptic fill-finish of injectable products. Comparable in scale and capability profile to Lifecore, serving similar small-to-mid pharma and biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Lifecore Biomedical social profiles

Digital presence

Lifecore Biomedical compliance and trust

Trust signal

Compliance6 records

Lifecore Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lifecore Biomedical leadership team

Management profile

Number of profiles

Profiles7 records

Lifecore Biomedical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lifecore Biomedical M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifecore Biomedical

What does Lifecore Biomedical do?

Lifecore Biomedical operates as a contract development and manufacturing organization (CDMO) providing end-to-end sterile injectable pharmaceutical services, including process development, aseptic formulation, fill-finish manufacturing (vials, syringes, cartridges), analytical testing, stability studies, and regulatory-compliant packaging. The company also produces premium sodium hyaluronate (NaHy) via microbial fermentation, sold as research-grade powder, hydrogels, methacrylated variants, and custom GMP-modified products for use as API, excipient, or research material.

Is Lifecore Biomedical a public or private company?

Lifecore Biomedical is a public company. It is classified as public and is currently operating.

When was Lifecore Biomedical founded?

Lifecore Biomedical was founded in 1965. It employs 251 to 500 people.

Where is Lifecore Biomedical based?

Lifecore Biomedical is headquartered in Chaska, United States, in the North America region.

How does Lifecore Biomedical make money?

Three revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are sodium Hyaluronate Products and development Services.

Who are Lifecore Biomedical's main competitors?

Direct peers on record are Societal CDMO, Catalent, Vetter Pharma, Recipharm, Alcami Corporation and Bloomage Biotech. Broad incumbents are Lonza Group, WuXi AppTec / WuXi Biologics and Thermo Fisher Scientific (Patheon). Grand River Aseptic Manufacturing is listed as an emerging player.

Does Lifecore Biomedical have an API?

No public API is recorded for Lifecore Biomedical.

What industry is Lifecore Biomedical in?

Lifecore Biomedical's product category is Sterile Injectable CDMO. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCRBrodsky & Smith notified investors of investigations into four merger deals: ADT, RXO, PTC, and Lifecore Biomedical. The deals involve cash and stock consideration, with enterprise values of $15.3B, $5.8B, $23.7B, and $6.28 per share respectively. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)Brodsky & Smith notified investors of investigations into four merger deals: ADT, RXO, PTC, and Lifecore Biomedical. The deals involve cash and stock offers with implied values of $15.3B, $5.8B, $23.7B, and $6.28 per share respectively. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process.PR NewswireAre BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating potential securities law violations in the proposed sales of Baldwin Group, Lifecore Biomedical, and Pacira BioSciences. The deals involve cash and contingent value rights, with the firm seeking increased consideration and additional disclosures on behalf of shareholders.PR NewswireAre BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating Baldwin Group, Lifecore Biomedical, and Pacira BioSciences for potential securities law violations and fiduciary breaches. The firm seeks increased consideration, additional disclosures, and other relief for shareholders in these proposed sales.American Banking and Market NewsLifecore Biomedical (NASDAQ:LFCR) vs. Bristol Myers Squibb (NYSE:BMY) Critical ComparisonBristol Myers Squibb outperforms Lifecore Biomedical on 12 of 15 comparison factors, including profitability and analyst ratings. Bristol Myers Squibb has a consensus target price of $65.46 with 4.81% upside, while Lifecore's is $6.50 with 1.56% upside. Bristol Myers Squibb's beta of 0.19 indicates lower volatility than Lifecore's 0.98.Business & FinancialBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors Of The Following Investigations: ADT Inc. (NYSE ADT), RXO Inc. (NYSE RXO), PTC Inc. (Nasdaq PTC), Lifecore Biomedical, Inc. (Nasdaq LFCR)Brodsky & Smith filed shareholder updates on investigations into four merger deals: ADT, RXO, PTC, and Lifecore Biomedical. The updates detail offer prices and enterprise values, such as ADT's $10 per share and $15.3 billion, and PTC's $205 per share and $23.7 billion. The investigations question whether boards breached fiduciary duties by failing to conduct fair processes.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCRBrodsky & Smith notified investors of investigations into four merger deals: ADT, RXO, PTC, and Lifecore Biomedical. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process and pay fair value. The firm invites shareholders to contact attorneys for further discussion.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)Brodsky & Smith notified investors of investigations into four companies' merger boards: ADT, RXO, PTC, and Lifecore Biomedical. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process and pay fair value. The firm offers no cost or financial obligation to shareholders.MarketBeatLifecore Biomedical (LFCR) Projected to Post Earnings on TuesdayLifecore Biomedical is expected to report Q3 2026 earnings on November 3rd, with analysts projecting a loss of $0.2975 per share and revenue of $25.57 million. The company's average analyst rating is "Reduce" with a consensus target price of $6.50.MarketBeatLifecore Biomedical, Inc. (LFCR) - What Are Analysts Saying About This Stock?Analysts rate Lifecore Biomedical a Reduce, with one sell and four hold ratings, and an average price target of $6.50. The company reported a loss of $0.19 per share for the quarter, matching estimates, and institutional investors own 83.36% of the stock.